Advertisement

PharmacoEconomics & Outcomes News

, Volume 813, Issue 1, pp 10–10 | Cite as

Elbasvir/grazoprevir dominates for chronic HCV in China

Clinical study
  • 6 Downloads

Reference

  1. Chen P, et al. Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China. Clinical Drug Investigation : 7 Sep 2018. Available from: URL: http://doi.org/10.1007/s40261-018-0702-9

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations